SLDB

Solid Biosciences Inc. (SLDB) | Rumor.io

Solid Biosciences

SLDB

Attention (50-day avg)0%

Attention rank (50-day avg)#839

Bullish sentiment (50-day avg)92%

Price to earnings ratio0.15

Market capitalization780.6M

Earnings per share-1.89

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-174.3M

Social

What share of all stock conversation is about SLDB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.3% new	0.03% +0.03	0.01% +0.01	0% 0

Jul 8

Investors are considering whether Solid Biosciences Inc. (SLDB) can break past its current price of $11.15 and maintain momentum.
Some investors see potential for bigger gains with SLDB currently at $11.15 and up 0.72%, while others consider it a buying opportunity or a gamble.
The future of SLDB's price is uncertain, with some predicting it can climb higher from $11.15 and others questioning whether the recent rise is a sign of things to come.

Generated by AI

Sentiment

Of the messages about SLDB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -40	96.32% +11.22
Bearish	—	—	40% new	3.68% -11.22

Bullish· Mar 1

Solid Biosciences Inc. has received an "outperform" rating from Charles Schawb.
The stock's indicators are signaling a buy, and a breakout above $5.83 could attract more investors.
The company has strong potential for growth, as evidenced by the "Here we go" sentiment, indicating a sense of optimism and excitement.

Bearish· Feb 18

The stock has experienced significant dilution, with 150% dilution near 52-week lows, which may lead to short selling.
The company's recent offering has been perceived as poorly timed, occurring shortly after news was released, and may be seen as a sign of weakness.
Institutional traders may sell their holdings at current levels, potentially leading to a further decline in price, as they may view the stock as overvalued.

Generated by AI

Topics

Of the messages about SLDB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	99.93%	99.52%	92.43%
Analysts	0%	0%	0.41%	4.38%
Technical Analysis	0%	0.07%	0.07%	2.59%
Controversies	0%	0%	0%	0.3%
Earnings	0%	0%	0%	0.3%
Macro	0%	0%	0%	0%

Analysts· Mar 16

SVB Leerink upgraded Solid Biosciences to Outperform with a price target of $15, citing encouraging data from the company's microdystrophin gene therapy trial.
Chardan Capital raised its price target on Solid Biosciences to $20, maintaining a Buy rating, due to the company's clinical improvement, especially in older patients.
Credit Suisse raised its price target on Solid Biosciences to $8, although maintaining a Neutral rating, after the company's microdystrophin gene therapy trial showed clean safety for the 7th patient dosed.

Announcements· Mar 6

Solid Biosciences (SLDB) announces an oversubscribed $240 million private placement, with institutional investors committing to purchase 14.97 million shares at $5.61 per share.
The company plans to use the proceeds for pipeline development, business development, and working capital, and has received commitments from major life-science investors, including Perceptive and Bain.
Solid Biosciences will present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, where it will discuss its pipeline expansion, including the next-generation gene therapy SGT-003 for Duchenne muscular dystrophy.

Technical Analysis· Feb 18

$SLDB needs to break off this downtrend here.
$SLDB broke from the downtrend and looking for more volume to keep this moving up!
$SLDB's positive trial data pushed it above $7, but the offering news weighed on upside momentum, with key support around $4.48.

Generated by AI

Community

Of the messages about SLDB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0.05%	0.92%	40.16%
Newcomers	100%	99.95%	99.08%	59.84%

Regulars· Feb 18

The data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy candidate, shows promising results with a high level of dystrophin expression.
The financing for Solid Biosciences includes new and existing investors, adding $200 million to the company's cash reserves, which brings the total market capitalization to less than $500 million, making the valuation attractive.
The company's data readout is comparable to that of Sarepta Therapeutics, a similar gene therapy company, and the safety profile of SGT-003 is a key concern for investors, with the need to maintain good safety through N=20 by YE25 for FDA approval.

Newcomers· Feb 18

$SLDB is a potential hot stock, but it broke down, and the author shorted the bounce, resulting in a stress-free green day.
The author has made a significant profit with $SLDB, with a +70% gain and room to run, and mentions the involvement of several notable investors.
The author is cautious about $SLDB due to 150% dilution near 52-week lows, which may attract short sellers, and expresses shame towards Twitter accounts promoting the stock.

Generated by AI

News

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB)

Solid Biosciences is leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. Learn more about SLDB stock here.

5d agoSeeking Alpha

Exclusive BAC Article: Solid Biosciences; FDA Meeting Q4 2026 For Potential AA Filing SGT-003 For DMD, Two Other Gene Therapy Readouts 1st Half 2027, Capsid Differentiation SGT-003, And Catalysts (NASDAQ:SLDB)

13d agoSeeking Alpha

Solid Biosciences wins new Outperform at RBC on DMD opportunity

13d agoSeeking Alpha

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

Solid Biosciences' (SLDB) differentiated approach to Duchenne muscular dystrophy and a "materially d

13d agoYahoo Finance

Cantor Fitzgerald reiterates Overweight on Solid Biosciences stock

13d agoInvesting.com

RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target

Solid Biosciences (SLDB) has an average rating of buy and mean price target of $18.62, according to

14d agoYahoo Finance

Also Discussed

Investors talking about SLDB also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	Sarepta Therapeutics, Inc.SRPT	0%-0.01
3	Wave Life Sciences Ltd.WVE	0%+0
4	KNTE - Kinnate Biopharma Inc.	——
5	TSVT - 2seventy bio, Inc.	——
6	KRTX - Karuna Therapeutics, Inc.	——
7	SGMO - Sangamo Therapeutics, Inc.	——
8	MRTX - Mirati Therapeutics, Inc.	——
9	ADVM - Adverum Biotechnologies, Inc.	——
10	Ovid Therapeutics Inc.OVID	0%0

Solid Biosciences Inc.

Healthcare
Biotechnology

Solid Biosciences Inc. is a precision genetic medicine company focused on developing gene therapy candidates for rare neuromuscular and cardiac diseases. Solid Biosciences Inc. advances a pipeline that includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and certain forms of dilated cardiomyopathy. Its work centers on addressing severe genetic disorders through targeted therapies designed to act on the underlying disease biology rather than on symptoms alone. The company serves the biotechnology and rare-disease markets, where its research and clinical development efforts are aimed at conditions with significant unmet medical need. Headquartered in Charlestown, Massachusetts, Solid Biosciences Inc. operates as a life sciences company with a focus on translating genetic science into treatments for patients with serious inherited diseases.

Website

Location

500 Rutherford Avenue

Charlestown, MA, 02129

United States

Social

What share of all stock conversation is about SLDB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.3% new	0.03% +0.03	0.01% +0.01	0% 0

Jul 8

Investors are considering whether Solid Biosciences Inc. (SLDB) can break past its current price of $11.15 and maintain momentum.
Some investors see potential for bigger gains with SLDB currently at $11.15 and up 0.72%, while others consider it a buying opportunity or a gamble.
The future of SLDB's price is uncertain, with some predicting it can climb higher from $11.15 and others questioning whether the recent rise is a sign of things to come.

Generated by AI

Sentiment

Of the messages about SLDB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -40	96.32% +11.22
Bearish	—	—	40% new	3.68% -11.22

Bullish· Mar 1

Solid Biosciences Inc. has received an "outperform" rating from Charles Schawb.
The stock's indicators are signaling a buy, and a breakout above $5.83 could attract more investors.
The company has strong potential for growth, as evidenced by the "Here we go" sentiment, indicating a sense of optimism and excitement.

Bearish· Feb 18

The stock has experienced significant dilution, with 150% dilution near 52-week lows, which may lead to short selling.
The company's recent offering has been perceived as poorly timed, occurring shortly after news was released, and may be seen as a sign of weakness.
Institutional traders may sell their holdings at current levels, potentially leading to a further decline in price, as they may view the stock as overvalued.

Generated by AI

Topics

Of the messages about SLDB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	99.93%	99.52%	92.43%
Analysts	0%	0%	0.41%	4.38%
Technical Analysis	0%	0.07%	0.07%	2.59%
Controversies	0%	0%	0%	0.3%
Earnings	0%	0%	0%	0.3%
Macro	0%	0%	0%	0%

Analysts· Mar 16

SVB Leerink upgraded Solid Biosciences to Outperform with a price target of $15, citing encouraging data from the company's microdystrophin gene therapy trial.
Chardan Capital raised its price target on Solid Biosciences to $20, maintaining a Buy rating, due to the company's clinical improvement, especially in older patients.
Credit Suisse raised its price target on Solid Biosciences to $8, although maintaining a Neutral rating, after the company's microdystrophin gene therapy trial showed clean safety for the 7th patient dosed.

Announcements· Mar 6

Solid Biosciences (SLDB) announces an oversubscribed $240 million private placement, with institutional investors committing to purchase 14.97 million shares at $5.61 per share.
The company plans to use the proceeds for pipeline development, business development, and working capital, and has received commitments from major life-science investors, including Perceptive and Bain.
Solid Biosciences will present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, where it will discuss its pipeline expansion, including the next-generation gene therapy SGT-003 for Duchenne muscular dystrophy.

Technical Analysis· Feb 18

$SLDB needs to break off this downtrend here.
$SLDB broke from the downtrend and looking for more volume to keep this moving up!
$SLDB's positive trial data pushed it above $7, but the offering news weighed on upside momentum, with key support around $4.48.

Generated by AI

Community

Of the messages about SLDB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0.05%	0.92%	40.16%
Newcomers	100%	99.95%	99.08%	59.84%

Regulars· Feb 18

The data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy candidate, shows promising results with a high level of dystrophin expression.
The financing for Solid Biosciences includes new and existing investors, adding $200 million to the company's cash reserves, which brings the total market capitalization to less than $500 million, making the valuation attractive.
The company's data readout is comparable to that of Sarepta Therapeutics, a similar gene therapy company, and the safety profile of SGT-003 is a key concern for investors, with the need to maintain good safety through N=20 by YE25 for FDA approval.

Newcomers· Feb 18

$SLDB is a potential hot stock, but it broke down, and the author shorted the bounce, resulting in a stress-free green day.
The author has made a significant profit with $SLDB, with a +70% gain and room to run, and mentions the involvement of several notable investors.
The author is cautious about $SLDB due to 150% dilution near 52-week lows, which may attract short sellers, and expresses shame towards Twitter accounts promoting the stock.

Generated by AI

Solid Biosciences

Social

Jul 8

Bullish· Mar 1

Bearish· Feb 18

Analysts· Mar 16

Announcements· Mar 6

Technical Analysis· Feb 18

Regulars· Feb 18

Newcomers· Feb 18

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB)

Exclusive BAC Article: Solid Biosciences; FDA Meeting Q4 2026 For Potential AA Filing SGT-003 For DMD, Two Other Gene Therapy Readouts 1st Half 2027, Capsid Differentiation SGT-003, And Catalysts (NASDAQ:SLDB)

Solid Biosciences wins new Outperform at RBC on DMD opportunity

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

Cantor Fitzgerald reiterates Overweight on Solid Biosciences stock

RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target

Also Discussed

Solid Biosciences Inc.

Company Information

Location

Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy’s Limitations (NASDAQ:SLDB)

Exclusive BAC Article: Solid Biosciences; FDA Meeting Q4 2026 For Potential AA Filing SGT-003 For DMD, Two Other Gene Therapy Readouts 1st Half 2027, Capsid Differentiation SGT-003, And Catalysts (NASDAQ:SLDB)

Solid Biosciences wins new Outperform at RBC on DMD opportunity

Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says

Cantor Fitzgerald reiterates Overweight on Solid Biosciences stock

RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target

Also Discussed

Social

Jul 8

Bullish· Mar 1

Bearish· Feb 18

Analysts· Mar 16

Announcements· Mar 6

Technical Analysis· Feb 18

Regulars· Feb 18

Newcomers· Feb 18